232 related articles for article (PubMed ID: 33317068)
61. Fe
Maddela S; Makula A; Galigniana MD; Parambi DGT; Federicci F; Mazaira G; Hendawy OM; Dev S; Mathew GE; Mathew B
Arch Pharm (Weinheim); 2019 Jan; 352(1):e1800174. PubMed ID: 30485473
[TBL] [Abstract][Full Text] [Related]
62. Design and synthesis of 2-amino-6-(1H,3H-benzo[de]isochromen-6-yl)-1,3,5-triazines as novel Hsp90 inhibitors.
Suda A; Kawasaki K; Komiyama S; Isshiki Y; Yoon DO; Kim SJ; Na YJ; Hasegawa K; Fukami TA; Sato S; Miura T; Ono N; Yamazaki T; Saitoh R; Shimma N; Shiratori Y; Tsukuda T
Bioorg Med Chem; 2014 Jan; 22(2):892-905. PubMed ID: 24369839
[TBL] [Abstract][Full Text] [Related]
63. Design and synthesis of pyrimidinyl acyl thioureas as novel Hsp90 inhibitors in invasive ductal breast cancer and its bone metastasis.
Koca İ; Özgür A; Er M; Gümüş M; Açikalin Coşkun K; Tutar Y
Eur J Med Chem; 2016 Oct; 122():280-290. PubMed ID: 27376491
[TBL] [Abstract][Full Text] [Related]
64. Design, synthesis and pharmacological evaluation of N-(5-chloro-2,4-dihydroxybenzoyl)-(R)-N-arylmethyl-1,2,3,4-tetrahydro-3-isoquinolinecarboxamides as potent Hsp90 inhibitors.
Liang C; Wu X; Li Z; Zhu J; Lu C; Shen Y
Eur J Med Chem; 2018 Jan; 143():85-96. PubMed ID: 29172085
[TBL] [Abstract][Full Text] [Related]
65. Discovery and Optimization of Small Molecules Targeting the Protein-Protein Interaction of Heat Shock Protein 90 (Hsp90) and Cell Division Cycle 37 as Orally Active Inhibitors for the Treatment of Colorectal Cancer.
Wang L; Jiang J; Zhang L; Zhang Q; Zhou J; Li L; Xu X; You Q
J Med Chem; 2020 Feb; 63(3):1281-1297. PubMed ID: 31935086
[TBL] [Abstract][Full Text] [Related]
66. Discovery of NMS-E973 as novel, selective and potent inhibitor of heat shock protein 90 (Hsp90).
Brasca MG; Mantegani S; Amboldi N; Bindi S; Caronni D; Casale E; Ceccarelli W; Colombo N; De Ponti A; Donati D; Ermoli A; Fachin G; Felder ER; Ferguson RD; Fiorelli C; Guanci M; Isacchi A; Pesenti E; Polucci P; Riceputi L; Sola F; Visco C; Zuccotto F; Fogliatto G
Bioorg Med Chem; 2013 Nov; 21(22):7047-63. PubMed ID: 24100158
[TBL] [Abstract][Full Text] [Related]
67. Multiclass comparative virtual screening to identify novel Hsp90 inhibitors: a therapeutic breast cancer drug target.
Dunna NR; Bandaru S; Akare UR; Rajadhyax S; Gutlapalli VR; Yadav M; Nayarisseri A
Curr Top Med Chem; 2015; 15(1):57-64. PubMed ID: 25579569
[TBL] [Abstract][Full Text] [Related]
68. Discovery of 5-aryl-3-thiophen-2-yl-1H-pyrazoles as a new class of Hsp90 inhibitors in hepatocellular carcinoma.
Mohamady S; Ismail MI; Mogheith SM; Attia YM; Taylor SD
Bioorg Chem; 2020 Jan; 94():103433. PubMed ID: 31785857
[TBL] [Abstract][Full Text] [Related]
69. Molecular mechanism of anticancer effect of heat shock protein 90 inhibitor BIIB021 in human bladder cancer cell line.
Asdemir A; Özgür A
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):5167-5177. PubMed ID: 38240781
[TBL] [Abstract][Full Text] [Related]
70. Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors.
Kusuma BR; Khandelwal A; Gu W; Brown D; Liu W; Vielhauer G; Holzbeierlein J; Blagg BS
Bioorg Med Chem; 2014 Feb; 22(4):1441-9. PubMed ID: 24461493
[TBL] [Abstract][Full Text] [Related]
71. Improving the Hsp90 Inhibitors Containing 4-(2,4-Dihydroxyphenyl)-1,2,3-thiadiazole Scaffold: Synthesis, Affinity and Effect on Cancer Cells.
Kazlauskas E; Brukstus A; Petrikas H; Petrikaite V; Cikotiene I; Matulis D
Anticancer Agents Med Chem; 2017 Nov; 17(11):1593-1603. PubMed ID: 28270068
[TBL] [Abstract][Full Text] [Related]
72. Targeting conserved water molecules: design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization.
Davies NG; Browne H; Davis B; Drysdale MJ; Foloppe N; Geoffrey S; Gibbons B; Hart T; Hubbard R; Jensen MR; Mansell H; Massey A; Matassova N; Moore JD; Murray J; Pratt R; Ray S; Robertson A; Roughley SD; Schoepfer J; Scriven K; Simmonite H; Stokes S; Surgenor A; Webb P; Wood M; Wright L; Brough P
Bioorg Med Chem; 2012 Nov; 20(22):6770-89. PubMed ID: 23018093
[TBL] [Abstract][Full Text] [Related]
73. Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors.
Park SY; Oh YJ; Lho Y; Jeong JH; Liu KH; Song J; Kim SH; Ha E; Seo YH
Eur J Med Chem; 2018 Jan; 143():390-401. PubMed ID: 29202402
[TBL] [Abstract][Full Text] [Related]
74. In Silico Discovery and Optimisation of a Novel Structural Class of Hsp90 C-Terminal Domain Inhibitors.
Zajec Ž; Dernovšek J; Gobec M; Tomašič T
Biomolecules; 2022 Jun; 12(7):. PubMed ID: 35883440
[TBL] [Abstract][Full Text] [Related]
75. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
Garg G; Khandelwal A; Blagg BS
Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
[TBL] [Abstract][Full Text] [Related]
76. BIIB021, an orally available and small-molecule inhibitor of HSP90, activates intrinsic apoptotic pathway in human cervical adenocarcinoma cell line (HeLa).
Güven CM; Özgür A
Eur Rev Med Pharmacol Sci; 2023 Aug; 27(15):7299-7308. PubMed ID: 37606138
[TBL] [Abstract][Full Text] [Related]
77. Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer.
Hyun SY; Le HT; Nguyen CT; Yong YS; Boo HJ; Lee HJ; Lee JS; Min HY; Ann J; Chen J; Park HJ; Lee J; Lee HY
Sci Rep; 2018 Sep; 8(1):13924. PubMed ID: 30224681
[TBL] [Abstract][Full Text] [Related]
78. Targeting the Hsp90 C-terminal domain to induce allosteric inhibition and selective client downregulation.
Goode KM; Petrov DP; Vickman RE; Crist SA; Pascuzzi PE; Ratliff TL; Davisson VJ; Hazbun TR
Biochim Biophys Acta Gen Subj; 2017 Aug; 1861(8):1992-2006. PubMed ID: 28495207
[TBL] [Abstract][Full Text] [Related]
79. BIIB021, a synthetic Hsp90 inhibitor, induces mutant ataxin-1 degradation through the activation of heat shock factor 1.
Ding Y; Adachi H; Katsuno M; Sahashi K; Kondo N; Iida M; Tohnai G; Nakatsuji H; Sobue G
Neuroscience; 2016 Jul; 327():20-31. PubMed ID: 27058144
[TBL] [Abstract][Full Text] [Related]
80. Synthesis and evaluation of a novel class Hsp90 inhibitors containing 1-phenylpiperazine scaffold.
Jia JM; Liu F; Xu XL; Guo XK; Jiang F; Cherfaoui B; Sun HP; You QD
Bioorg Med Chem Lett; 2014 Mar; 24(6):1557-61. PubMed ID: 24582477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
